1. Home
  2. RNTX vs MNY Comparison

RNTX vs MNY Comparison

Compare RNTX & MNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • MNY
  • Stock Information
  • Founded
  • RNTX 2001
  • MNY 2014
  • Country
  • RNTX United States
  • MNY Singapore
  • Employees
  • RNTX N/A
  • MNY N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • MNY
  • Sector
  • RNTX Health Care
  • MNY
  • Exchange
  • RNTX Nasdaq
  • MNY Nasdaq
  • Market Cap
  • RNTX 40.3M
  • MNY 43.9M
  • IPO Year
  • RNTX N/A
  • MNY N/A
  • Fundamental
  • Price
  • RNTX $1.16
  • MNY $1.93
  • Analyst Decision
  • RNTX
  • MNY Strong Buy
  • Analyst Count
  • RNTX 0
  • MNY 1
  • Target Price
  • RNTX N/A
  • MNY $4.00
  • AVG Volume (30 Days)
  • RNTX 56.1K
  • MNY 642.5K
  • Earning Date
  • RNTX 08-13-2025
  • MNY 09-18-2025
  • Dividend Yield
  • RNTX N/A
  • MNY N/A
  • EPS Growth
  • RNTX N/A
  • MNY N/A
  • EPS
  • RNTX N/A
  • MNY N/A
  • Revenue
  • RNTX N/A
  • MNY $71,649,746.00
  • Revenue This Year
  • RNTX N/A
  • MNY $16.97
  • Revenue Next Year
  • RNTX N/A
  • MNY $19.35
  • P/E Ratio
  • RNTX N/A
  • MNY N/A
  • Revenue Growth
  • RNTX N/A
  • MNY N/A
  • 52 Week Low
  • RNTX $1.04
  • MNY $0.55
  • 52 Week High
  • RNTX $4.40
  • MNY $2.15
  • Technical
  • Relative Strength Index (RSI)
  • RNTX N/A
  • MNY 65.73
  • Support Level
  • RNTX N/A
  • MNY $1.60
  • Resistance Level
  • RNTX N/A
  • MNY $2.05
  • Average True Range (ATR)
  • RNTX 0.00
  • MNY 0.23
  • MACD
  • RNTX 0.00
  • MNY -0.02
  • Stochastic Oscillator
  • RNTX 0.00
  • MNY 63.24

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.

Share on Social Networks: